Max India Limited (MAXIND) has announced a significant enhancement to its senior-care division, Antara Senior Care, with the appointment of Dr Rachit Gulati as a specialist in Physical Medicine & Rehabilitation (PMR), Pain Management, and Rheumatology at its Care Home in Gurugram. This strategic move is aimed at bolstering Antara’s post-operative, transition, and high-dependency care for adults aged 18 and above, including seniors recovering from surgery, serious illness, or prolonged hospitalization.

Specialized Expertise in Rehabilitation

Dr Gulati brings over a decade of experience in clinical practice, healthcare leadership, and developing comprehensive rehabilitation services. His clinical expertise spans spinal cord injury, traumatic brain injury, Parkinsonism, stroke rehabilitation, musculoskeletal and rheumatological disorders, chronic pain management, and interventional physiatry. Notably, he holds an MBBS and an MD in Physical Medicine & Rehabilitation, along with a Fellowship in Pain Medicine and a Certificate in Rheumatology (EULAR).

Comprehensive Care Ecosystem

Antara’s Care Homes offer specialized short-term post-operative and transition care, along with long-term high-dependency care, for adults aged 18 and above, including seniors. Care is doctor-led and backed by nursing and clinical depth, with individualised rehabilitation plans that bring together physiotherapy, spinal cord rehabilitation, speech and swallow therapy, nutrition and dietetics, fall prevention, and catheter and feeding tube care, tailored to each patient’s clinical needs and recovery goals. The appointment of Dr Gulati further strengthens this clinical approach, bringing specialized expertise in rehabilitation and pain management to support better recovery outcomes.

As a result, Antara aims to support patients through a structured recovery journey and help them return to their everyday routines with greater confidence and independence. This strategic addition to the team underscores Max India Limited’s commitment to enhancing the quality of life for its senior care clientele.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max India Limited

Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 13.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.

Fermenta Biotech Limited (FERMENTA) has announced its consolidated financial results for the half year ended September 30, 2026 (H1FY27). The company reported consolidated revenue of INR 261.9 crore, a 7% year-on-year decline. The EBITDA and profit after tax for the period were INR 45.6 crore and INR 18.9 crore respectively, down 34% and 52% year-on-year.

Revenue Breakdown

The revenue for the period was primarily driven by the Human Nutrition segment, which now accounts for close to two-thirds of the total revenue. The Vitamin D3 – Human Nutrition business saw a 2% growth despite a 13% year-on-year decline in volumes. The Vitamin D3 – Animal Nutrition segment experienced a significant drop, with volumes down 31% and average realization down 35% year-on-year.

Geographical Revenue Shift

India has emerged as the largest market for FERMENTA, contributing 51% of the consolidated revenue in H1FY27, up from 40% a year earlier. This shift underscores the company’s strategic focus on steadier markets while navigating the price cycle in animal nutrition.

Forward-Looking Statements

Prashant Nagre, Managing Director of Fermenta Biotech Limited, emphasized the company’s balanced approach, highlighting the FSSAI approval for VITADEE Green® and the expected readiness of Calcifediol by the end of FY27. He also noted the benefits of the company’s listing on the National Stock Exchange (NSE), which has broadened investor access.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fermenta Biotech Limited

Fermenta Biotech Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Fermenta rises 12.3% over three months, with buying pressure holding steady. Revenue grows at 14.5% CAGR. The company generates cash but does not compound aggressively. The stock holds at 38% of its 52-week range with RSI at 43. In other words, neither side has a clear edge right now. Revenue grows at 14.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Fermenta Biotech Limited.

Shilpa Medicare Limited (SHILPAMED) has announced record earnings for the 2nd quarter and the first half of FY27, marking a significant milestone for the company. The financial results highlight robust growth across all business segments, driven by strategic initiatives and strong market demand.

Financial Highlights

In the 2nd quarter of FY27, Shilpa Medicare Limited reported its highest-ever quarterly revenue of INR 538 crores, marking a 45% year-over-year (YoY) growth. The earnings before interest, taxes, depreciation, and amortization (EBITDA) also reached a new high at INR 151 crores, up 37% YoY. The profit after tax (PAT) surged to INR 79 crores, an 80% increase from the previous year.

Full-Year First Half Performance

For the first half of FY27, the company’s total income crossed the INR 1,000 crore mark for the first time, growing 44% YoY to INR 1,007 crores. The EBITDA grew 40% YoY to INR 290 crores, maintaining a stable margin of 29%. The PAT nearly doubled to INR 180 crores, with the PAT margin expanding to 18%.

Strategic Focus and Future Outlook

The company’s focus on innovation-led differentiation has paid off, evidenced by high-value partnerships such as the expanded collaboration with Orion Corporation for the development and supply of Nivolumab biosimilar in Europe. With a maturing pipeline and a sharpened strategic focus, Shilpa Medicare Limited is well-positioned to deliver stronger performance for the remainder of FY27.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Shilpa Medicare Limited

Shilpa Medicare Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Shilpa gains 51.2% over three months and trades near its 52-week highs. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 51.2% in three months on 13.8% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Shilpa Medicare Limited.